The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

scicann.net

About SciCann Therapeutics

SciCann Therapeutics is a Canadian-Israeli specialty pharmaceutical company, dedicated to the development and commercialization of pharmaceutical products that target and modulate the endocannabinoid system. SciCann Therapeutics is active in the fields of inflammatory disorders, oncology and neurodegenerative diseases and develops a line of cannabinoid-based products for the treatment of chosen life-threatening conditions that present a high level of unmet need.

SciCann Therapeutics Headquarter Location

69 Yonge St., Suite 1010

Toronto, Ontario, M5E 1K3,

Canada

+972 52 733 1424

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing SciCann Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

SciCann Therapeutics is included in 2 Expert Collections, including Cannabis.

C

Cannabis

3,834 items

These companies participate in - or service businesses that participate in - the legal cannabis industry. Our definition of cannabis includes both marijuana and hemp (and all derivatives). The collection includes both "plant-touching" and "non-plant-touching" businesses.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

SciCann Therapeutics Patents

SciCann Therapeutics has filed 4 patents.

The 3 most popular patent topics include:

  • Cannabinoids
  • Combination drugs
  • Designer drugs
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/28/2019

4/6/2021

Cannabinoids, Designer drugs, Phenols, Combination drugs, Medicinal plants

Grant

Application Date

11/28/2019

Grant Date

4/6/2021

Title

Related Topics

Cannabinoids, Designer drugs, Phenols, Combination drugs, Medicinal plants

Status

Grant

Latest SciCann Therapeutics News

FSD Pharma's Investments Provide Unique Diversification -- CFN Media

Mar 5, 2019

| Source: CFN Media SEATTLE, March 05, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing  FSD Pharma Inc.  (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9). The company is best known for its 3.8 million square foot former  Kraft Foods facility  in Cobourg, Ontario, which could make it one of the largest licensed producers in the country, if approved by Health Canada. In addition to this massive footprint, the company has established many strategic alliances that have gone under-the-radar for many investors, but could generate significant long-term value. The Canadian cannabis industry is projected to reach C$22.6 billion over the coming years, according to Deloitte, driven by the legalization of adult-use cannabis last year. With the upcoming legalization of edibles this fall, the market could significantly expand its addressable market beyond consumers willing to smoke cannabis. These dynamics could help lift the value of many different companies operating in the space. In this article, we will take a look at the company’s four strategic investments as well as other partnerships that they have in place to drive long-term shareholder value. Cannara Biotech Cannara Biotech  is an aspiring licensed producer that recently purchased a modern 625,000 sq. ft. facility on 27 acres of land in Quebec — less than an hour away from Montreal. In addition to owning over 85 million shares of the company, FSD Pharma will lease over 105,000 sq. ft. of the facility for the purpose of cultivating and/or selling cannabis or cannabis-derived products, creating another key venue to cultivation. SciCann Therapeutics SciCann Therapeutics  is an Israeli firm that has become one of the leaders in cannabis research. With access to its network of leading researchers, academic institutions and medical centers, FSD Pharma is free to conduct rigorous clinical studies for cannabis-based products in a highly time and cost-efficient environment. The company invested an undisclosed amount in the company for these purposes. High Tide Ventures High Tide Ventures  is a fully-integrated retail distribution company that has applied for more than 30 retail cannabis permits in Alberta and 16 in Saskatchewan. In addition, the company plans to submit an application in British Columbia in the near-term. The company owns four of Canada’s most prominent retail brands that are poised to take advantage of the nascent recreational market. FSD Pharma made a strategic investment in the firm. Huge Shops Huge Shops invested $1.3 million for a 9.9% ownership interest in Huge Shops, a Toronto-based cannabis retailer. The company has a strategic alliance with Chairman’s Brands/Coffee Time — a well-established operator of retail coffee shops with more than 75 locations in Canada and other locations worldwide. As part of the investment, Huge Shops has an option to acquire a minimum of ten of these retail locations. Additional Partnerships FSD Pharma has signed several strategic partnerships aside from its four strategic investments. These partnerships include collaborations, revenue-sharing agreements, licensing agreements, and research agreements that could pay dividends over time. The company’s major partnerships include: Canntab Therapeutics: Canntab has developed patent-pending technology that provides a uniform dose of medical cannabis extract, including sustained-release options for targeted indications. Under their agreement, the company will manufacture its products in FSD Pharma’s Cobourg facility in exchange for a profit-sharing deal. World-Class Extractions: World Class has developed unique extraction processes designed to produce higher concentrations of cannabinoids, processes larger quantities, reduce production time, and utilize all parts of the plant. FSD Pharma has a license agreement in place to utilize the technology. Solarvest: FSD Pharma signed a letter of intent with Solarvest to develop and test pharma-grade cannabinoid creation from algae. The process could reduce the production time for pharmaceutical grade cannabinoids by up to 95 percent — potentially revolutionizing the industry. Pharmastrip: Pharmastrip has developed a cannabis-infused oral thin film technology using organic cannabis extracts. Under the terms of their deal, FSD Pharma has exclusive, perpetual rights to manufacture and sell the strips in Canada and Pharmastrip’s technology will be installed in FSD Pharma’s Cobourg facility. Looking Ahead FSD Pharma Inc.  (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) may be best known for its massive Cobourg, Ontario production facility that’s in the process of becoming licensed, but investors shouldn’t ignore the company’s strategic investments and partnerships. These agreements help diversify its exposure to the industry, and could generate significant long-term shareholder value. For more information, visit the company’s website at  www.fsdpharma.com . Please follow the link to read the full article and see the interview:  https://www.cannabisfn.com/fsd-pharmas-investments-provide-unique-diversification/ About CFN Media CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed. Learn how to become a CFN Media client company, brand or entrepreneur:  http://www.cannabisfn.com/featuredcompany Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand:  https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8 Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone:  http://www.cannabisfn.com Disclaimer CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on  http://www.cannabisfn.com  (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news. The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation:  http://www.cannabisfn.com/legal-disclaimer/ Frank Lane

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.